Pegfilgrastim: The promise of pegylation fulfilled

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 6-7

  Crawford, J ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; BODY WEIGHT; BONE PAIN; BREAST CANCER; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG INDICATION; EDITORIAL; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; LYMPHOMA; MYELODYSPLASIA; NEUTROPENIA; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK ASSESSMENT; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THORAX CANCER; TREATMENT OUTCOME; UNITED STATES;

EID: 0037249412     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg036     Document Type: Editorial

References (15)

1. Crawford JC, Blackwell S. Hematopoietic growth factors. In Perry MC (ed): The Chemotherapy Source Book, 3rd edition. Philadelphia, PA: Lippincott Williams and Wilkins 2001; 94-105.
2. Ozer H, Annitage JO, Bennett CL et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558-3585.
3. Citron M, Beery D, Cirrincione C et al. Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGFB 9741, INT C9741). Paper presented at 25th Annual San Antonio Breast Cancer Symposium, 12 December 2002, San Antonio, TX (Abstr 15).
4. Crawford J, Ozer H, Stoller R et al. Reduction in the incidence of chemotherapy-induced febrile neutropenia in patients with small cell lung cancer by granulocyte colony-stimulating factor (R-metG-CSF). N Engl J Med 1991; 325: 164-171.
5. Crawford J. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Drugs 2002; 62 (Suppl 1): 79-88.
6. Roskos LK, Yang B, Schwab G et al. A cytokinetic model of r-metHuG-CSF-SD/01 (SD/01) mediated granulopoiesis and the "self-regulation" of SD/01 elimination in non-small cell lung cancer (NSCLC) patients. Blood 1998; 92 (Suppl 1): 507a (Abstr).
7. Johnston E, Crawford J, Blackwell S et al. Randomized dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
8. Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
9. Holmes FA, O'Shaughnessy J, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
10. Pegfilgrastim prescribing information. Thousand Oaks, CA: Amgen 2002.
11. Vose JM, Crum M, Lazarus H et al. Single dose pegfilgrastim (SD/01) is as effective as daily filgrastim following ESHAP chemotherapy for subjects with non-Hodgkin's lymphoma or Hodgkin's disease: results of a randomized, open label study. Blood 2001; 98: 799a (Abstr 3322).
12. Calhoun EA, Change C-H, Welshman EE et al. A neutropenia-specific quality of life instrument: rationale for the development of the FACT-N. Proc Am Soc Clin Oncol 2002; 21: 375a (Abstr 1498).
13. Kuderer NM, Cosler L, Crawford J et al. Cost and mortality associated with febrile neutropenia in adult cancer patients. Proc Am Soc Clin Oncol 2002; 21: 250a (Abstr 998).
14. Lyman GH, Lyman CH, Ogboola Y. Risk models for the prediction of chemotherapy-induced neutropenia. Neutropenia Oncol 2001; 1: 2-7, 12.
15. Lyman GH, Kuderer NM, Balducci L. Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol 2002; 9: 207-214.